摘要
目的：探讨良性前列腺增生症（BPH）患者经过药物治疗后夜尿情况。方法将2014年1~6月在北京市怀柔地区多个社区卫生服务中心就诊的BPH患者148例作为研究对象。所有患者均接受α受体阻滞剂和（或）5α还原酶抑制剂药物治疗，均在治疗前后接受国际前列腺症状评分（I-PSS），并在治疗后行3 d排尿日记记录和尿常规、前列腺特异性抗原（PSA）及经直肠前列腺B超检查。结果药物治疗后，BPH 患者 I-PSS、刺激性症状评分、梗阻性症状评分、生活质量评分均较治疗前降低，差异均有统计学意义（P〈0.01）；而BPH患者药物治疗前后夜尿评分比较，差异无统计学意义（P＞0.05）。148例BPH患者中，76.4%（113/148）的BPH患者为夜间尿量增多（NP）型夜尿，夜尿次数为（2.3±1.1）次，夜尿量为（845.7±339.0）mL。BPH患者夜尿量与夜尿次数、睡前4 h饮水量、单次最大排尿量及晨尿量相关（r=0.419、0.402、0.445、0.440，P=0.002、0.031、0.001、0.001）。NP型和非NP型下尿路症状（LUTS）病史、夜尿量、晨尿量、日间排尿次数、睡前4 h饮水量比较，差异均有统计学意义（P＜0.05）。结论 BPH患者经过α受体阻滞剂和（或）5α还原酶抑制剂药物治疗后，LUTS得到一定程度的改善，但许多患者夜尿缓解效果不满意。
Objective To investigate the nocturia onset situation after medication therapy in the patients with benign prostatic hyperplasia（BPH）. Methods A total of 148 patients with BPH in the community health service centers of Beijing Huairou area were selected. All patients received the medication therapy of α-receptor blocker and/or 5αreductase inhibitors,evaluation of the International Prostate Symptom Score（I-PSS） after medication and performed the 3 d urination diary,urinary routine,prostate-specific antigen（PSA） detection and transrectal prostate ultrasonography. Results The scores of I-PSS, stimulating symptom, obstructive symptoms and living quality after the medication therapy were reduced compared with before treatment ,the difference was statistically significant（P〈0.01）. The score of night urination in the BPH patients had no statistical difference between before and after treatment （P〉0.05）. Among 148 BPH patients,76.4%（113/148） of BPH patients were nocturnal polyuria（NP）type,the nocturnal urination times were（2.3±1.1）times,nocturnal urine volume was（845.7±339.0）mL. The nocturnal urine volume of BPH patients was correlated with the nocturnal urination number,water intake volume at 4 h before sleep,single maximal urination volume and first morning urine volume（r=0.419,0.402,0.445,0.440,P=0.002,0.031,0.001,0.001）. The lower urinary tract symptoms（LUTS） history,nocturnal urine volume,first morning urine volume,daytime urination frequency and water intake volume at 4 h before sleep had statistically significant differences between the NP type patients and non-NP type patients（P〈0.05）. Con-clusion LUTS after the medication therapy of α-receptor blocker and/or 5α reductase inhibitors of the BPH patients are im-proved to some extent,but nocturnal enuresis relief in many patients is not satisfactory.
出处
《现代医药卫生》
2016年第15期2328-2330,共3页
Journal of Modern Medicine & Health
关键词
前列腺增生
夜尿
生活质量
前列腺特异抗原
药用制剂
北京
Prostatic hyperplasia
Nocturia
Quality of life
Prostate-specific antigen
Pharmaceutical preparations
Beijing
